JPC 46 • DECEMBRE - McGill...

Poster/abstract

submission deadlineMay 30th

2011

Endorsed by

Win2011[A5]2ndA:Mise en page 1 12/04/11 17:21 Page1

Worldwide Innovative Networking in personalized cancer medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

Dear Colleague,

The Worldwide Innovative Networking (WIN) Consortium invites you to attend the third WINAnnual Symposium, dedicated this year to a very challenging topic: Gateways to increasingthe efficacy of cancer diagnostics and therapeutics.

The WIN Consortium, initiated by Institut Gustave Roussy (France) and The University of TexasMD Anderson Cancer Center (USA), is a non-profit organization bringing together cancercenters from five continents to address the challenge of increasing the efficacy of global cancerhealthcare through personalized therapy. The WIN Consortium aims to foster and facilitatecooperation between cancer centers, pharmaceutical and technology companies, patientadvocacy groups, governmental institutions and other stakeholders in the field of early diagnosisand personalized, biomarker-driven treatment of cancer. The goal is to accelerate integrationof groundbreaking discoveries into clinical practice in diverse populations, in order to significantlyimprove clinical outcomes and the quality of life of cancer patients, worldwide.

Examples of questions for discussion and debate during WIN3 include: • Determining the efficacy of targeted cancer therapies• Determining the efficacy of genetic and molecular biomarkers for selecting

patients likely to respond to targeted therapeutics• Improved design of clinical trials with targeted therapies. Efficient

comparisons. Appropriate endpoints. Combinations of therapies. Is randomization necessary?

• Building more effective collaborations between academia, industry and patients.

• Innovation in technologies that identify genetic and molecular abnormalities in cancers.

• Improvements in bioinformatics and applications of systems biology.

We aim to create a forum for open discussion, in which your expertise and input from all sta-keholders in cancer drug development are crucial. The WIN Consortium was created to acceleratethe pace and reduce the cost of translating effective cancer treatments to the bedside. Weneed every member and thought leader in the field to be committed and engaged to succeedin our mission.

The 22 founding member institutions of the WIN Consortium invite you to join in this forum,and we invite you and your institution to join the Consortium (http://www.winconsortium.org).

JOHN MENDELSOHN, M.D.Chairman of WIN Consortium

President of University of Texas MD Anderson Cancer Center


What WIN Consortium offers

An opportunity to make an impact on cancer across the globe by increasing the number of patients havingaccess to innovative clinical trials and treatment with the latest innovative drugs

WIN Consortium aims to accelerate the drugdevelopment process with:

> Worldwide basis for innovative biomarker driven clinical trials Diversity is the most important asset of WIN, which makes it unique and different from any other initiative. Our patients come from four continents (Asia, North and South America, Europe) plus the Middle East. Each clinical trial will involve a diverse population of patients who share an aberrant genetic function in their tumors, but have different genetic backgrounds and life-styles that may impact responses to a therapy – a tremendous advantage in early Phase I/II studies.

> Access to experienced and active research and clinical investigators in prestigious academic oncology centers

> Access to high quality, innovative technology platforms

> Support and expertise of outstanding technology partners(Agilent Technologies, Life Technlologies and GE Healthcare)

> Simultaneous conduct of trials in several cancer centers andseveral countries

> Continuity of preclinical, phase I, II and III clinical trials upto successful registration

> Standardization of procedures: biobanking, laboratory methods,enrollment of patients, quality assurance, and protocol review

Fo r m o re i n fo r m a t i o n o n h ow t o j o i n t h e W I N C o n s o r t i u m , c o n t a c t u s o n

www.winconsortium.orgor at WIN secretary office at [email protected]


Academic Institutes and Non-profit Organizations

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC),Tata Memorial Centre Mumbai [India]

Ben-Gurion University of the Negev Beer Sheva [Israel]

Fondazione IRCCS Istituto Nazionale dei Tumori Milan [Italy]

Fudan University Shanghai Cancer Center Shanghai [China]

Fundaçao Pio XII, Hospital de Câncer de BarretosPius XII Foundation Barretos Sao Paulo [Brazil]

Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (VHIO) Barcelona [Spain]

Hadassah University Medical Center Jerusalem [Israel]

Institut de Cancérologie Gustave Roussy Villejuif [France]

Institute for Digestive Diseases and Liver Transplantation (ICBDTHF) Bucharest [Romania]

King Hussein Cancer Center Amman [Jordan]

National Breast Cancer Foundation Texas [United States]

National Cancer Centre Singapore [Singapore]

The Oncology Institute Ion Chiricuta (IOCN) Cluj-Napoca [Romania ]

Sage Bionetworks Seattle [United States]

Segal Cancer Centre, Jewish General Hospital, McGill University Montreal [Canada]

Semmelweis University, Faculty of Medicine, 1st Departmentof Pathology and Experimental Cancer Research Budapest [Hungary]

Chaim Sheba Medical Center [Israel]

The University of Medecine and Pharmacy Iuliu Hatieganu Cluj-Napoca [Romania]

The University of Texas MD Anderson Cancer Center Houston, Texas [United States]

Associated Technology Partners

Agilent Technologies California [United States]

General Electric Healthcare Chalfont St. Giles [United Kingdom]

Life Technologies Corporation Foster City [United States]

Founders of the WIN Consortium


WIN Consortium Operational TeamWIN Consortium Secretary Office at Institut Gustave Roussy.114 avenue Edouard Vaillant 94800 Villejuif, France. Tel: 33 (0) 142 11 40 20 – Email : [email protected] Operating Officer: Vladimir LazarDirector of Operational Team: Catherine Bresson

3rd WIN Annual Symposium Organizing CommiteeJohn Mendelsohn, Alexander Eggermont, Richard L.Schilsky, Vladimir Lazar,Catherine Bresson, Michael Bia

Win Consortium LeadershipChairman: John Mendelsohn, The University of Texas MD Anderson Cancer CenterVice-Chairman: Thomas Tursz, Institut Gustave RoussyChairman of the Scientific Advisory Board: Richard L. Schilsky, University of ChicagoChief Operating Officer: Vladimir Lazar, Institut Gustave Roussy

WIN Consortium Scientific Advisory BoardChairman:Richard L. Schilsky, University of Chicago

Co-Chairman:Leroy Hood, Institute of Systems Biology

Phillip Febbo UC-San FranciscoDaniel Hayes University of MichiganDavid Tuveson Cancer Research UKGuido Kroemer INSERM-Institut Gustave RoussyLaura Van T Veer Hellen Diller Family CCC, UC-San FranciscoGary Rosner Sidney Kimmel Comprehensive Cancer Center John HopkinsYves Lussier University of ChicagoJulio Celis Danish Cancer SocietyJi Zhang State Key Laboratory of Medical Genomics/ RuiJIN Sino-French Center of Life ScienceManfred Schmitt Frauenklinic und Poliklinik der Technischen Universitaet MünchenStanley Hamilton University of Texas MD AndersonDonald Berry University of Texas MD AndersonManohar Furtado Life Technologies CorporationNeil Cook Agilent TechnologiesIan Wilson GE Healthcare






Wednesday, July 6th, 20117:30 REGISTRATION

8:15 WELCOME AND OPENING OF THE SYMPOSIUM

ALEXANDER EGGERMONT, DIRECTOR OF THE INSTITUT GUSTAVE ROUSSY

8:30 KEYNOTE LECTURE

JOHN MENDELSOHN, CHAIRMAN OF WIN CONSORTIUM ANDPRESIDENT OF UNIVERSITY OF TEXAS MD ANDERSON CANCERCENTER, USAChallenges and opportunities in personalized cancer therapy andcooperation between the Pharmaceutical Industry and Academia.The WIN Consortium model and operational goals

SESSION 1: THE ERA OF PERSONALIZED MEDICINE AND OF SIGNIFICANT PROGRESS FOR PATIENT CAREChairmen: Stephen Friend, President Sage Bionetworks, USA.

Nick Botwood, Vice-President Clinical Oncology, Astra Zeneca, UK

8:55 MIKE BURGESS, GLOBAL HEAD OF ROCHE PHARMA ONCOLOGYRESEARCH AND EARLY DEVELOPMENT AND LARGE MOLECULERESEARCHDawn of the personalized healthcare era: a significant step forwardin patient care

9:20 PAUL BILLINGS, CHIEF MEDICAL OFFICER OF LIFETECHNOLOGIES, USAGenomic Cancer Care Alliance TACT Trial: multi-center feasibilitystudy for whole genome sequencing in therapy selection: Challenges for academics and industry

The three fundamental changes needed to improvecurrent healthcare

9:45 DAVID SIDRANSKY, JOHNS HOPKINS UNIVERSITY, USA Predict efficacy of therapeutics in day to day clinics: experimentalmodels versus directly exploring tumor molecular portraits




10:10 D. GARY GILLILAND, SENIOR VICE PRESIDENT AND GLOBALONCOLOGY FRANCHISE HEAD, MERCK AND CO. Predicting efficacy of therapeutics in clinical trials: filling the gapbetween pre-clinical models and phase I clinical trials

10:45 SAMIR HANASH, FRED HUTCHINSON CANCER CENTER, USAEarly diagnostics: a clue for enhanced global efficacy in oncology:Joining WIN Consortium for a global effort to detect lung cancersin earlier stage

11:10-11:30 Coffee Break, network discussions and poster review

SESSION 2: CHALLENGES OF COMBINING TARGETEDTHERAPIESChairmen: Richard L. Schilsky, Chairman of WIN Scientific Advisory Board, University of Chicago, USA

Fabrice André, Institut Gustave Roussy, France

11:30 ROBERT WASSERMAN, VICE PRESIDENT, PHC STRATEGIC EXPERTOF ROCHE PHARMA ONCOLOGY RESEARCH AND EARLYDEVELOPMENTVemurafinib (a BRAF inhibitor) - The thrill of efficacy and thechallenge of emerging tumor resistance

11:50 RAZELLE KURZROCK, CHAIR, DEPARTMENT OF INVESTIGATIONALCANCER THERAPEUTICS-PHASE I PROGRAM, UT-MDANDERSONCANCER CENTER, USA

12:10 SHANNON MORRIS, DIRECTOR, EARLY DEVELOPMENT UNIT,CANCER RESEARCH, GLAXOSMITHKLINE ONCOLOGYAcademic and Pharmaceutical Industry perspective: Increasingthe predictive value of early phase clinical trials to screen new agents or combinations likely to be efficacious in a defined patient population

12:30 ROUND TABLE - PANEL OF EXPERTS - FORUM OF OPEN DISCUSSIONWITH ATTENDEESMonotherapies or combined therapeutics? Clinically addressing thecomplexity of molecular pathways in cancer: How can we developthe most relevant combination beyond individual Pharma/Biotechpipelines: a risk sharing approach for the benefit of the patient Garry Gilliland, MERCK, Nick Botwood, ASTRA ZENECA, Mike Burgess, ROCHE,John Mendelsohn, Chairman of the WIN Consortium, Richard L.Schilsky, Chairmanof the SAB of the WIN Consortium, Alexander Eggermont, Director of the InstitutGustave Roussy, Karim Fizazi, Institut Gustave Roussy, France

13:15-14:40 Lunch, network discussions and poster review




13:15-14:40 CONCURRENT WORKSHOPS

Workshop of the WIN Consortium Committee on standardization of biobanking and molecular analyses of biopsiesin clinical trials (open to the public)

Organizers: Amir Onn, Chaim Sheba Medical Center, Israel, Stanley Hamilton, UT-MDAnderson Cancer Center, USA with participation of Vladimir Lazar, Institut GustaveRoussy, France, Gerald Batist, Segal Cancer Centre, Canada, Ioana Neagoe, IOCN,Romania, Rita Mulherkhar, ACTREC TATA Memorial Hospital, India, Dingwey Ye,Fudan University Shanghai Cancer Centre, China, Ignacio. I Wistuba, UT-MDAnderson,USA. The Workshop will present the final results from the Biosy-guided CT scan genomic signature from the BATTLE trial at UT-MDACC, USA.

Workshop of the WIN Consortium Committee on auditand compliance in clinical trials (open to the public)

Organizers: Richard L. Schilsky, University of Chicago, Chairman of SAB of WINConsortium and Soo Khee Chee, National Cancer Centre Singapore with participationof André Lopes Carvalho, Hospital De Câncer de Barretos, Brasil, Salmon Asher,Sharret Institut of Oncology Hadassah Israel and Mahmoud Sahran, King HusseinCancer Center, Jordan, Gilles Vassal, Institut Gustave Roussy, France, Lajos Pusztai,UT-MD Anderson Cancer USA

SESSION 3: NEW BIOMARKER STRATEGIES INCLINICAL TRIALSBiomarkers and their intended uses for treatment decisionsand drug development decisionsChairmen: Samir Hanash, Fred Hutchinson Cancer Center, USA

D. Gary Gilliland, Senior Vice President and Global Oncology Franchise Head, Merck and Co

14:40 IAN A. WILSON, HEAD OF BIOLOGY, GE HEALTHCARE MEDICALDIAGNOSTICSMolecular Diagnostics and Functional imaging

15:05 LILLIAN SIU, PRINCESS MARGARET HOSPITAL TORONTO, CANADAPharmacogenomic testing - matching patients with targeted drugs

15:30 DOMINIQUE STOPPA-LYONNET, INSTITUT CURIE, FRANCEGenetic background, susceptibility to cancer, and impact onpersonalized medicine

15:55 DONALD BERRY, UNIVERSITY OF TEXAS MD ANDERSON CANCERCENTER, USAUsing biomarkers prospectively in adaptive trials




16:20 VLADIMIR LAZAR, CHIEF OPERATING OFFICER OF WIN CONSORTIUM,INSTITUT GUSTAVE ROUSSY, FRANCE A comprehensive and adaptive model of biomarker strategies in clinicaltrials. Highlights of the WIN Consortium workshop on standardization and use of biopsies

16:55 ULI ROHR, ROCHE DIAGNOSTICS, PENZBERG, GERMANYPerspective of a diagnostic company on personalized healthcare:making a diagnostic: from understanding the medical environmentto the ultimate definition and validation of the test


SESSION 4: STRATEGIC ALLIANCES TO FIGHT CANCERChairmen: John Mendelsohn, Chairman of WIN Consortium, President of UT MD

Anderson Cancer Center, USAAlexander Eggermont, Director Institut Gustave Roussy, France

17:40 GAIL ECKHARDT, UNIVERSITY OF COLORADO SCHOOL OF MEDICINE, USAUS Academic/Industry collaborations for predictive biomarkers in earlyclinical development: perspectives of joining WIN Consortium efforts

18:00 DENIS LACOMBE, DIRECTOR, EORTC, BELGIUMMolecular driven clinical trials: the EORTC Network of CoreInstitutions (NOCI) and perspectives of interactions with WINConsortium

18:20 JULIO E. CELIS, DANISH CANCER SOCIETY, DENMARKEfforts by the European cancer community to reinforce cooperation andincrease global efficacy in therapeutics. Achievements andperspectives: a specific role for WIN Consortium

18:40 JANELLE AND KEVIN HAIL, NATIONAL BREAST CANCERFOUNDATION, USABeyond the shock of cancer disease: Education worldwide, prevention and their impact on improving quality of life of cancer patients

19:00 WELCOME COCKTAIL




Thursday, July 7th, 2011

7:30 REGISTRATION

SESSION 5: DISCOVERY AND VALIDATION OF NEW TARGETSAND BIOMARKERSChairmen: Daniel Louvard, Head of Research, Institut Curie, France

Soo Khee Chee, National Cancer Centre, Singapore

8:30 LEROY HOOD, CO-CHAIRMAN OF WIN SAB, PRESIDENT OF INSTITUTEOF SYSTEMS BIOLOGY, SEATTLE, USA Integrating pre-clinical models with clinical data - drivers andpassengers

8:55 ROBERT KERBEL, SUNNYBROOK HEALTH SCIENCES CENTER, CANADA Improving the prospects of preclinical models to predict investigationaldrug efficacy in the clinic and clinical trials

9:20 STEPHEN FRIEND, SAGE BIONETWORKS, USAHow do we study network perturbations in clinical specimens? Howdo we select “drivers” of malignancies?

9:45 KENNETH ANDERSON, DANA FARBER CANCER INSTITUTE, USANew targets and innovative therapeutics

10:10 SAMIT HIRWAT, VICE-PRESIDENT, NOVARTISAn example: Targeting the PI3K pathway - focused developmentfor the treatment of cancer

10:35 PANEL OF EXPERTS - FORUM OF OPEN DISCUSSIONWITH ATTENDEESInnovative and informative pre-clinical models and translation to clinic





SESSION 6: WIN-WIN MODELS: CONCEPTS FOR SUCCESSChairmen: Dingwey Ye, Fudan University Shanghai Cancer Center, China

Amir Onn, Chaim Sheba Medical Center, Israel

11:30 MARCO PIEROTTI, ISTITUTO NAZIONALE DEI TUMORI, ITALY Academic perspective: how to share ideas, resources and intellectualproperty? What are the Win-Win models?

11:50 ANTONELLA ISACHI, DIRECTOR NERVIANO MEDICAL SCIENCES, ITALY A successful interaction between Academia and Pharma –The NERVIANO Medical Sciences – and Oncology Network of Lombardy

12:10 WILIAM VAINCHENKER, INSERM, INSTITUT GUSTAVE ROUSSY,FRANCE JAK 2 – from basic concepts to clinical diagnostics and therapeuticsapplications

12:30-14:00 Lunch, network discussions and poster review

12:30-14:00 CONCURRENT WORKSHOPS

Workshop of the WIN Consortium Scientific Committeeon the design of clinical trials, data processing and access(open to the public)

Organizers: Razelle Kurzrock, UT MDACC, USA and Jean-Charles Soria,Institut Gustave Roussy, France with participation of Donald Berry, UTMDACC, USA, Soo Khee Che, National Cancer Centre, Singapore, StephenFriend, SAGE Bionetworks, USA, Josep Tabernero, VHIO, Spain and excep-tional participation of Nick Botwood, ASTRA ZENECA, Mike Burgess, ROCHEand Garry Gilliland, MERCK

Workshop of the WIN Consortium Publicity and Fundraising TaskForce (open to the public)

Organizers: Janelle Hail, NBCF, USA and Mark Vossenaar, Agilent Techno-logies, with participation of John Mendelsohn, Chair of WIN Consortium,Alexander Eggermont, Director Institut Gustave Roussy, Vladimir Lazar,Chief Operating Officer of WIN Consortium, and exceptional participation ofCoen van Veenendaal and Peter Kapitein, Inspire2Live organization




Workshop of the WIN Consortium Committee on membership(not open to the public)

Organizers: Gerald Batist, Segal Cancer Centre, Canada and Robert Dann,GE Healthcare, with participation of Marco Pierotti, Istituto Nazionale DeiTumori, Italy, Catherine Bresson, Director of operations of WIN Consortium,Angel Porgador, Ben Gurion University of Negev, Israel and Oliver Bogler,UT MD Anderson Cancer Center, USA

SESSION 7: STRATEGIES TO IMPROVE EFFICIENCYOF CLINICAL TRIALSChairmen: Donald Berry, UT MD Anderson Cancer Center, USA

Mike Burgess, Global Head of ROCHE Pharma Oncology Research and EarlyDevelopment and Large Molecule Research

14:00 JEAN-CHARLES SORIA, HEAD OF EARLY CLINICAL TRIALS ANDINNOVATIVE THERAPEUTICS UNIT, INSTITUT GUSTAVE ROUSSY,FRANCEChallenges in early drug development

14:25 NICK BOTWOOD, DEVELOPMENT DIRECTOR LATE ONCOLOGYPORTFOLIO, ASTRA ZENECA Gateways to increased efficacy of drug development: From phase IIto successful phase III and registration

14:50 RICHARD GOLDBERG, CHIEF OF HEMATOLOGY AND ONCOLOGY,NORTH CAROLINA CANCER HOSPITAL, UNIVERSITY OF NORTHCAROLINA AT CHAPEL HILL, USAPredicting clinical efficacy: Molecular and radiographic markersas heralds of drug response.

15:15 FORUM OF OPEN DISCUSSION WITH ATTENDEESFrom random to patient selected clinical trials: How should competingtrials be prioritized? Defining thresholds for improved efficiencyin clinical trials?


SESSION 8: BREAKTHROUGH CONCEPTS ANDTECHNOLOGIES DEVELOPMENTS Chairmen: Arturo Galvani, Director NERVIANO Medical Sciences, Italy

Vladimir Lazar, Chief Operating Officer of WIN Consortium, Institut Gustave Roussy, France




16:30 LEO BONILLA, DIRECTOR FOR LIFE SCIENCE RESEARCH, AGILENTTECHNOLOGIES Integration of multi-omics & biomarker strategies

16:55 MARTIN NALEY, HEAD OF MEDICAL NEXT GENERATION SEQUENCING,LIFE TECHNOLOGIESMedical next generation sequencing: Translational medicine aimingto improve health care efficiency

17:20 LUDOVIC LACROIX, INSTITUT GUSTAVE ROUSSY, FRANCEUniversal Biomarker Cancer (UBM) technology: a joint developmentof Institut Gustave Roussy-Life technologies

17:45 STEVE PENNINGTON, SCHOOL OF MEDICINE AND MEDICAL SCIENCE,UCD CONWAY INSTITUTE, UNIVERSITY COLLEGE DUBLIN, IRELANDPersonalized proteomics for cancer - unrealistic promises or truepotential?

18:10-18:30 Refreshment break

SESSION 9: THE URGENT NEED FOR INCREASED ACCESSOF PATIENTS FROM DIVERSE POPULATIONS TOINNOVATIVE CLINICAL TRIALS Chairmen: John Mendelsohn, Chairman of WIN Consortium, President of UT MD Anderson Cancer Center, USA

Alexander Eggermont, Director Institut Gustave Roussy, France

18:30 CHRIS VIEHBACHER, CHAIRMAN AND CEO, SANOFI AVENTIS, FRANCEPersonalized medicine, and the future of drug development:a challenge for academia and pharmaceutical industry and a truehope for patient

19:00 RICHARD L. SCHILSKY, CHAIRMAN OF WIN SCIENTIFICADVISORY BOARD, UNIVERSITY OF CHICAGO, USAPersonalized medicine, synthesis of the 3rd WIN annual symposiumand perspectives

19:30 PETER KAPITEIN, INSPIRE2LIVE, THE NETHERLANDSA perspective from patient advocacy: The urgent need to translatescientific progress to improve the life of cancer patients

20:30 GALA DINNER




Friday, July 8th, 2011

8:30-12:30General Assembly of the WIN Consortium (business meeting,restricted to members and open to non members by requestand invitation only)Chairman: John Mendelsohn, Chairman of WIN Consortium, President of UT MDAnderson Cancer Center, USA

Request for invitations at: WIN Consortium Secretary Office: Institut GustaveRoussy; 114 Rue Edouard Vaillant, 94800 Villejuif, France - Vladimir Lazar, ChiefOperating Officer: e-mail: [email protected]

8:30-12:3010 meeting rooms will be at your disposal for intervals of45 minutes. Reservations may be made online at www.mfcongres.com from June 15th.

THE EXHIBITION AREA ANDMEETING ROOMS WILL BE OPEN

AND AT THE DISPOSALOF ALL ATTENDEES UNTIL 12:30

COFFEE AND TEA WILL BE AVAILABLE


With thanks toour Media Partners

Sponsors of the WIN Symposium

NBCF is a founding member of the WIN Consortium created in 2010. Janelle Hail,founder and CEO of NBCF is a member of the board of directors and the steeringcommittee of the WIN Consortium. The role of NBCF is sharing expertise in orga-nizing structures and fundraising, and organizing educational and prevention ef-forts worldwide to improve quality of life of cancer patients. WIN Consortiumproudly announces in it 3rd WIN Annual Symposium a breakthrough achievementof NBCF: Beyond the Shock educational program.

BEYOND THE SHOCK®

Beyond the Shock® is a comprehensive, multi-cultural online guide to understandingbreast cancer. Created by the National Breast Cancer Foundation, Inc. (NBCF), it is aresource for women who have been diagnosed with breast cancer, a place for lovedones to gain a better understanding of the disease, and a tool for doctors to share in-formation with their patients. Beyond the Shock® is currently being translated in mul-tiple languages with the mission to bring hope around the world. For more informationvisit: www.beyondtheshock.com

JANELLE HAILFounder & CEO of the National Breast Cancer Foundation, Inc.

Janelle Hail, a 30-year breast cancer survivor, is the Founder & CEOof the National Breast Cancer Foundation, Inc. (NBCF), one of themost highly recognized and respected breast cancer charities in theworld. She founded NBCF in 1991 with a dream in her heart to providewomen with resources to help them live long, productive lives.Through her leadership, NBCF has received numerous honors and isconsidered the voice of hope in the breast cancer community. As an

award-winning writer and professional speaker, Janelle has traveled across the U.S.and around the world inspiring women with her message of hope and NBCF’s missionto save lives through early detection and to provide mammograms for those in need.This mission includes increasing awareness through education, providing diagnosticbreast care services for those in need, and providing nurturing support services.

KEVIN HAILCOO of the National Breast Cancer Foundation, Inc.

Kevin Hail is the Chief Operating Officer for the National BreastCancer Foundation, Inc. NBCF was founded in 1991 by Mr. Hail’s mo-ther and breast cancer survivor, Janelle Hail. Since its inception, heworked as a volunteer and business consultant with NBCF. In 2005,Mr. Hail joined NBCF as the organization’s full-time COO, and usedhis business leadership experience to help NBCF grow exponentially.

Since his appointment as COO, NBCF has grown by an average of20% each year. Mr. Hail also helped launch some of the most innovative programs inAmerica’s non-profit sector, including www.mynbcf.org, an online community forbreast cancer survivors, the Early Detection Plan®, an interactive reminder system tohelp women schedule regular breast cancer screenings, and NBCF’s new educationflagship, Beyond the Shock®, the web’s best breast cancer education resource.


01• The abstract should be sent by e-mail ([email protected]) or downloaded on the website:www.mfcongres.com, if this is not possible, you can send it by mail to the Conference Secretariat or byfax: +33 1 40 07 10 94.

02• The abstract should be written in Word format (95 or higher).03• Abstracts should be submitted in English.04• The entire abstract should be included within the format of one abstract text to be included within the format

of height 12.5 cm (4.92 inches) and width 9 cm (3.54 inches) and 250 words max.05• The abstract should be single-spaced, using Arial 10 point font, and must be fully justified. DO NOT use a

smaller font, as the abstract will later be reduced to 70% of the size for printing in the abstract book.06• The abstract title (2 lines maximum) should clearly define the content of the paper. In the title use only bold

capital letters and no abbreviations. Do not centre, start at the left margin.07• Type the author’s initials followed by family name, title (MD, PhD, RN, Pod, Phys Ther) followed by the co-

authors’ names (maximum 5), the name and address of the institution for each author, e-mail of the presen-ting author.

08• The e-mail address box should be filled in properly for correspondence purposes.09• Structure the abstract following IMReD (Introduction, Methods, Results, Discussion)10• In case of support by a grant, please indicate the source of funding. Disclosure must be indicated.11• Charts or graphs should be inserted in the abstract (files from separate software cannot be implemented).12• Number references (if any) in the order in which they appear in the text.13• Indicate the category (topic) into which the abstract should fit in.

Abs

trac

t ins

truc

tion

s

Contact informationFamily name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . First name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Title . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Institution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Zip code . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . City . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Country . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Phone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Fax number . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

E-mail . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Call for poster/abstract

Insert your abstract

Your abstract should be received by the Conference Secretariat (8 rue Tronchet, 75008 Paris, France)[email protected] by May 30th, 2011 or on the web site: www.mfcongres.comThe authors will be informed of the Symposium Organizing Commitee’s decision before June 15th, 2011.

Submit on the website: www.mfcongres.com or by e-mail: [email protected]

The best five posters will be granted free attendance


Badges

All participants will receive their name badge onsite.This badge cannot be exchanged and must be wornduring the sessions.

Bank opening times

Banking hours in Paris are usually from 9 am to 5 pm,Monday to Friday. In the rest of France, banks are usuallyopen from 10 am to 1 pm and from 3 pm to 5 pm, Tues-day to Saturday. Banks often close early on the daybefore a bank holiday.

Carpark

The Palais des Congrès has an underground carparkwith direct access to the Congress centre (Capacityof 1800 spaces). Cost not included in registration fee.

Certificate of attendance

Participating delegates will receive a Certificate ofAttendance.

Climate

The weather in Paris in July is usually warm with anaverage temperature of 25°C during the day.

Currency and foreign exchange

The national currency is EURO. Currency can beexchanged at all bank branches and Post Offices.“Bureaux de change” can also be found in large depart-ment stores, railway stations, airports and near touristattractions. Please note: although the exchange rate

is fixed, commission rates are not. These must be clearlydisplayed.

Disclaimer

The Organising Committee and MF Congrès cannotaccept liability for any injury or loss incurred by parti-cipants and/or persons accompanying them, nor forloss of, or damage to, their luggage and/or personalbelonging.

Electricity

The power supply is 220 V, 50 Hz. Round Europeanstyle two-pin plugs are used. Appliances designed tooperate on 110/120 V require a voltage converter anda plug adapter.

Language

The official language of the Congress is English.

Local time

The time zone in Paris is GMT +1 hour.

Meals

Coffee/tea are included in the registration fee and willbe served daily during the coffee breaks. A lunch boxis included in the registration fee.

Smoking policy

Please note that smoking is not permitted in theCongress.



Pratical information


Travel information

Package information (flight + accommodation) willbe available on the website: www.mfcongres.com

From the airport to the Palais des Congrès. An air-port shuttle operated by Air France departs from RoissyCharles de Gaulle airport every 12 minutes. The busstops just outside the Palais des Congrès and oppositethe Meridien Etoile hotel. The bus fare from the airportto the city of Paris is around 13 Euros. Local number82, 73, 43, 244 buses and the Petite Ceinture (PC)also stop at the Congress centre. On the RER, takeline C and alight at Neuilly-Porte Maillot-Palais desCongrès station and by Metro, take Line 1 and alightPorte Maillot station. (www.ratp.com)Car rental:All the large companies have offices bothat the airport and in the city. Driving information:Speed limits in France are as follows: on motorways130 km/h, on other roads 90 km/h, and in all citiesand villages 50 km/h.

Venue

The 3rd WIN Symposiumwill be held at:

Palais des Congrès2, Place de la Porte Maillot, 75017 Paris, France

Tél: +33 (0)1 40 68 22 22Fax: +33 (0)1 40 68 27 40

The Palais des Congrès of Paris is situated in PorteMaillot, and is connected to the city centre, as well asto the airports and train stations, by metro and buses.For all the information you may need during your stayin Paris (travel, metro plan, social events, museumsetc.), please visit the website: www.paris.fr. The websiteis very comprehensive and is available in English.

You can contact the Paris Tourist Office at+ 33 (0) 892 68 31 12. and www.parisinfo.com

Symposium secretary Worldwide InnovativeNetworking in personalized cancer medicine

8, rue Tronchet75008 Paris (France)

Tel.: +33 (0)1 40 07 11 21Fax: +33 (0)1 40 07 10 [email protected]

Registration onlinewww.mfcongres.com

Official Carrier THE BEST PRICE FOR YOURAIR TICKET

Get the best price for your flight withAir France and KLM Global Meetings.Valid for travel from 01/07/2011to 13/07/2011Event ID Code to keep forthe booking: 11339AFMore details: www.airfranceklm-globalmeetings.com

TRAIN (SNCF) REDUCTIONS Up to 20% reduction on full price return rail tickets (within France). Reduction

vouchers can be ordered from the meeting secretary (see registration form) and will be sent with the confirmation of registration.




Name Address PreferentialSymposium

RatesComments

LE MÉRIDIENETOILE ****

AT THE CONVENTION

CENTER

81 bd Gouvion St Cyr75017 PARISTél: +33 (0)1 40 07 11 21Fax: +33 (0)1 40 07 10 [email protected]

• Classic room, single or double:225 €

• Breakfastincluded

• Reception and business center 24 hours a day.

• Wifi in public areas.

• Explore our 2 restaurantsl’Orénoc and the Jazz Club Lounge.

• Enjoy live concerts at the Jazz Club.

HOTELSTAR

CHAMPS ELYSEES

***

10 minutes walking distance18 rue de l’Arc de Triomphe 75017 PARISTél: +33 (0)1 43 80 27 69Fax: +33 (0)1 40 54 94 [email protected]

• Classique single: 145€

• Classic double:160€

• Buffetincluded

• Non smoking hotel

• Free Wifi

HOTELREGENT’SGARDEN

BESTWESTERNPREMIER

****

8 minutes walking distance6 rue Pierre DEMOURS75017 PARISTél: +33 (0)1 45 74 07 30Fax: +33 (0)1 40 55 01 [email protected]

• Classic single/double: 220€

• Superior Single/double: 250 €

• Buffet included

• Non smoking and ecolabel adoptedapproach

• Free Wifi, mini bar offered in soft drinks,bath robe, largerooms between15 to 30 m2.






Professional addressCompany name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Family name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

First name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Address: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Zip code: . . . . . . . . . . . . . . . . . . . . . . City: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Country: . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Phone: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fax: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

E-mail: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

I would like to receive _____ discount (20%) vouchers for SNCF train travel. Air France: Event ID Code to keep for the booking: 11339AF. Valid for travel from 01/07/2011 to 13/07/2011

BANK ACCOUNT: 30056 CODE POSITION: 00062 CODE ACCOUNT: 0062 013 8071 N°KEY: 28 DOMICILIATION: HSBC FR PARIS OPERA

IBAN: FR76 3005 6000 6200 6201 3807 128 – BIC: CCFRFRPP

HSBC FR PARIS OPERA

Registration fees Before July 3rd, 2011 After July 3rd, 2011

• Companies, Biotech: 3 days €675 €775 • Institutes, Universities, Public agencies: 3 days €475 €575

Hotel registration

Hotel Meridien****L. 81 boulevard Gouvion St Cyr. 75017 Paris. www.lemeridien.com/etoilePrice includes breakfast €225 x _______________ Night(s)Check in: ___ / 07/2011 Check out: ___ / 07/2011 _____ Night(s) Single occupancy Double occupancy

Total = ______________€ �

Gala dinner €150 x ______________ Person (s) = ______________€

Total = ______________ € �

Find enclosed a cheque/bank draft made payable to MF CONGRES for: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . �€Find enclosed the copy of the bank transfer. Payable to MF CONGRES for: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . �€Payment by credit card .................. MASTER CARD VISA AMEX

Number:Expiry date:

Signature

Registration online: www.mfcongres.com

Registration Form

Pre-registration

Cancellation Policy Symposium secretaryRegistration cancellations must be notified before July 1st, 2011. There will be no refunds for cancellations received after this date. A processing fee of €150 will be charged for all cancellations. Refunds will be processed after the meeting.

MF Congres. 8, rue Tronchet - 75008 Paris - France Phone: +33 (0)1 40 07 11 21 – Fax: +33 (0)1 40 07 10 94E-mail: [email protected]

before July 3rd, 2011 (after July 3rd, 2011 registration is onsite)


JPC 46 • DECEMBRE - McGill...

Documents

Transcript of JPC 46 • DECEMBRE - McGill...